M. BEKTAŞ Et Al. , "High-dose intravenous anakinra treatment is safe and effective in severe and critical COVID-19 patients: a propensity score-matched study in a single center," INFLAMMOPHARMACOLOGY , vol.31, no.2, pp.787-797, 2023
BEKTAŞ, M. Et Al. 2023. High-dose intravenous anakinra treatment is safe and effective in severe and critical COVID-19 patients: a propensity score-matched study in a single center. INFLAMMOPHARMACOLOGY , vol.31, no.2 , 787-797.
BEKTAŞ, M., YÜCE, S., Ay, M., Uyar, M. H., oender, M. E., & Kilic, M. I., (2023). High-dose intravenous anakinra treatment is safe and effective in severe and critical COVID-19 patients: a propensity score-matched study in a single center. INFLAMMOPHARMACOLOGY , vol.31, no.2, 787-797.
BEKTAŞ, Murat Et Al. "High-dose intravenous anakinra treatment is safe and effective in severe and critical COVID-19 patients: a propensity score-matched study in a single center," INFLAMMOPHARMACOLOGY , vol.31, no.2, 787-797, 2023
BEKTAŞ, Murat Et Al. "High-dose intravenous anakinra treatment is safe and effective in severe and critical COVID-19 patients: a propensity score-matched study in a single center." INFLAMMOPHARMACOLOGY , vol.31, no.2, pp.787-797, 2023
BEKTAŞ, M. Et Al. (2023) . "High-dose intravenous anakinra treatment is safe and effective in severe and critical COVID-19 patients: a propensity score-matched study in a single center." INFLAMMOPHARMACOLOGY , vol.31, no.2, pp.787-797.
@article{article, author={Murat BEKTAŞ Et Al. }, title={High-dose intravenous anakinra treatment is safe and effective in severe and critical COVID-19 patients: a propensity score-matched study in a single center}, journal={INFLAMMOPHARMACOLOGY}, year=2023, pages={787-797} }